Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY900020 · 1 trial · 1 indication
PK: AUC of LY900020
PK: Cmax of LY900020
| Arm | Type | Description |
|---|---|---|
| LY900020 Formulation 1 | EXPERIMENTAL | LY900020 Formulation 1 administered orally |
| LY900020 Formulation 2 | EXPERIMENTAL | LY900020 Formulation 2 administered orally |
| LY900020 Formulation 3 | EXPERIMENTAL | LY900020 Formulation 3 administered orally |
| Reference Drugs | ACTIVE_COMPARATOR | Metformin XR, atorvastatin, and valsartan administered orally |
| Name | Type | Description |
|---|---|---|
| LY900020 | DRUG | Administered orally |
| Metformin XR | DRUG | Administered orally |
| Atorvastatin | DRUG | Administered orally |
| Valsartan | DRUG | Administered orally |
Inclusion Criteria: * Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion) * Have a body mass index (BMI) of 18.5 to 35 kilogram per square meter (kg/m²), inclusive, at screening * Have normal blood pressure, pulse rate, electrocardiogr...
LY900020 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other. As of now, it is not approved and remains in clinical trials.
LY900020 is being studied for use in healthy participants. The completed Phase 1 trial evaluated the drug in healthy Chinese participants. Its specific therapeutic indication has not been established, and it is in early-stage clinical development to assess safety and tolerability.
LY900020 is developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker LLY. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
LY900020 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug is still investigational. It has not been approved by regulatory authorities, and further clinical studies would be needed to assess its safety and efficacy.
LY900020 has one completed clinical trial, NCT04047940, titled "A Study of LY900020 in Healthy Chinese Participants." This Phase 1 study enrolled 32 participants in Singapore, with a minimum age of 21 years, and included both sexes. The trial was active-controlled and randomized.
LY900020 is a unique investigational drug candidate developed by Eli Lilly and Company. No alternative names have been reported for this compound. It is a small molecule in early clinical development, and its mechanism of action has not been disclosed in available information.